SOLVO Biotechnology Newsletter

		15 September 2006
	Newsletter

SOLVO Biotechnology has significantly expanded its Contract Screening portfolio offering now a unique integrated service platform to evaluate the membrane transporter profiles of drug candidates at various pharmacological barriers and transporter mediated drug-drug interactions.

SOLVO services include not only the standard Monolayer assays, but it focuses also on all the major efflux and uptake trasnporters present at the major pharmacological barriers offering individual HTS assay systems for each transporter that enables the in depth analysis of tranporter-drug and transporter mediated drug-drug interactions.

Comprehensive Contract Research Services: cover the following assays:

Efflux Transporter Assays
ATPase Assays	human Pgp / MDR1 (ABCB1) rat Mdr1b human MRP1 (ABCC1) human MRP2 (ABCC2) rat Mrp2 human MRP3 (ABCC3) human BCRP / MXR (ABCG2)
Vesicular Transport Assays	human MRP1 (ABCC1) human MRP2 (ABCC2) human MRP3 (ABCC3) human MRP5 (ABCC5) human BCRP / MXR (ABCG2) human BSEP / sPgp (ABCB11) mouse bsep Under development: human MRP6 mouse Bcrp rat Bsep ABCA1, ABCG5/G8
Cellular Dye Transport Assays	human Pgp / MDR1 (ABCB1) human MRP1 (ABCC1) human BCRP / MXR (ABCG2)

Whole Cell Assays	Uptake Transporter Assays:
	rat Ntcp human OATP1B1 (OATP2, OATP-C) human OATP1B3 (OATP8) human OATP2B1 (OATP-B) rat Oatp1a1 (Oatp1) Under development: human NTCP (SLC10A1) rat Oatp2 (Oatp1a4) rat Oatp4(Oatp1b2) human PEPT1 (SLC15A1) human PEPT2 (SLC15A2)

Monolayer Permeability Assays:

Unidirectional permeability of the test compound on Caco2 cells.
Unidirectional permeability of the test compound on MDCKII (parental) cells.
Unidirectional permeability of the test compound on Caco2 cells in the presence of specific inhibitors.
Bidirectional permeability of the test compound on Caco2 cells.
Bidirectional permeability of 3H-digoxin in the presence of the test compound (PgP DDI model).

Extensive Service Development Pipeline: In the next 18 months SOLVO will establish and validate a complex Pharmacokinetic Technological Platform that integrates, correlates and harmonizes DMPK and ADME-Tox (in vitro, ex vivo and in vivo) research systems including the following elements:

Vectorial assays with multiply transfected (efflux and uptake transporters) cell lines
Physiological Barrier Models (in vitro and ex vivo): Blood-Brain-Barrier, Liver, Intestinal, Cardiac, Skin;
Toxicity Micro-array
Transporter chip - allows the measurement of drug induced transporter expression alterations
Transporter humanized knock-out, knock-in animals
Cross Validated Compound Database - that enables the predictive determination and characterization of drug - membrane transporter and transporter mediated drug-drug interactions for all molecules in any phase of the drug development process.

Most major pharmaceutical and biotechnology companies utilize our products and services in their drug discovery development pipeline.

For further information and a detailed research proposal please contact SOLVO Biotechnology.

Best regards,
SOLVO Biotechnology
Business Development Team

For Customers in Japan: Funakoshi (distributor of SOLVO membrane products) Iwaki (exclusive distributor of SOLVO Fee-for Service Screenings, distributor of SOLVO membrane products)

Privileged/confidential information may be contained in this message. This communication is confidential and intended solely for the addressee(s). Unauthorized distribution, modification or disclosure of the contents may be unlawful. If you receive this in error, please notify the sender and delete it from your system. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone.

If you wish to unsubscribe, please send a letter to

with 'unsubscribe' in the subject field.

15 September 2006